Deals and Financings   Shanghai Zai Lab announced two in-licensings: a $615 million deal for two cancer drugs from Blueprint and a $187 million agreement for a Karuna psychiatric drug; I-Mab formed a $315 million collaboration with Hubei Jumpcan Pharma to commercialize I-Mab's human growth hormone in  China ; Arbor Biotech, a  Cambridge   MA  gene editing company, raised $215 million in an oversubscribed B round led by Temasek and Ally   Bridge ; Shanghai 's Ignis Therapeutics, which was spun out from  South Korea 's SK Biopharma, raised an initial $180 million to bring SK's CNS drug assets to  China ; Hopstem Biotech, a China-US stem-cell therapy company, completed a near $40 million B financing from Lilly Asia Ventures and YuanBio Venture Capital; Hangzhou 's Ascletis Pharma extended its viral disease partnership for Alphamab's PD-L1 to include global rights;  Trials and Approvals   Everest Medicines said its novel TROP-2 antibody-drug conjugate met its primary endpoint in a China Phase II trial in triple-negative breast cancer patients; Ascletis Pharma of  Hangzhou  was approved to start a China Phase II clinical trial of its PD-L1 candidate in HIV-1 patients as a possible cure of HIV-1; Gmax Biopharm, a novel  Hangzhou  antibody company focused on GPCRs, has begun a China Phase I trial of its obesity therapy; Nanjing IASO Bio dosed the first patient in a China Phase I/II trial of its fully human CD19/CD22 CAR-T cell therapy for non-Hodgkin's lymphoma.  Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: KRTX) (NSDQ: IMAB) (SHA: 600566) (HK; 1672) (HK 1952) (HK: 1672) Share this with colleagues: // //